Company overview
Basic information
Company name
Advicept, MB
Company code
306067215
VAT code
LT100014963510
Registered address
Jonava, Lietavos g. 3-45, LT-55153
Registration date
2022-04-21
Company age: 4 y. 6 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
None
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Legal activities
Ownership form
Private without foreign capital
Advicept, MB
Company code: 306067215
Address: Jonava, Lietavos g. 3-45, LT-55153
VAT code: LT100014963510
Description
This description was generated by artificial intelligence.
Advicept, MB (company code 306067215) is a private small partnership registered in 2022 and operating as of the latest record. It is classified as a micro-sized entity in the national private non-financial companies sector, with a governance structure of CEO only and private ownership, where Lithuanian natural and legal persons hold more than 50% of the authorised capital and there is no foreign investor capital. The company’s core activity is N.69.10.00 Legal activities. It is based in Jonava, Jonava District Municipality, Kaunas County, at Lietavos g. 3-45.
Financially, Advicept recorded revenue of EUR 297.3 thousand in 2025, broadly stable year on year after EUR 296.8 thousand in 2024 and EUR 270.8 thousand in 2023. Net profit declined to EUR 147.9 thousand in 2025 from EUR 184.1 thousand in 2024, while the net profit margin stood at 49.8% in 2025. The company’s equity increased to EUR 529.6 thousand, total assets reached EUR 536.9 thousand, and liabilities remained low at EUR 7.3 thousand. The latest indicators also show a strong equity position and moderate revenue growth over the two-year period.
Financially, Advicept recorded revenue of EUR 297.3 thousand in 2025, broadly stable year on year after EUR 296.8 thousand in 2024 and EUR 270.8 thousand in 2023. Net profit declined to EUR 147.9 thousand in 2025 from EUR 184.1 thousand in 2024, while the net profit margin stood at 49.8% in 2025. The company’s equity increased to EUR 529.6 thousand, total assets reached EUR 536.9 thousand, and liabilities remained low at EUR 7.3 thousand. The latest indicators also show a strong equity position and moderate revenue growth over the two-year period.
Download a detailed company report
Make confident decisions with all the information about Advicept, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.